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We review here our experiences with the in vitro reprogramming of somatic cells to induced pluripotent stem cells (iPSC) and
subsequent in vitro development of hematopoietic cells from these iPSC and from embryonic stem cells (ESC). While, in principle,
the in vitro reprogramming and subsequent diﬀerentiation can generate hematopoietic cell from any somatic cells, it is evident
that many of the steps in this process need to be signiﬁcantly improved before it can be applied to human cells and used in clinical
settings of hematopoietic stem cell (HSC) transplantations.
1.Introduction
The in vitro generation of hematopoietic stem cells (HSC)
and mature hematopoietic cells from embryonic stem cells
(ESC) promises to provide an alternative source of cells
that could replace total bone marrow cells or HSC-enriched
fractions of them. This is especially necessary in the case of
human cells in clinical settings for HSC transplantations. In
addition, studying hematopoiesis in vitro bypasses the need
of donor cells, in particular to study hematopoietic disorders
in human. ESC lines can be cultured long term and allow,
in contrast to HSC, homologous recombination of DNA,
that is, the insertion of exogenously modiﬁed genes into the
appropriate sites in the genome. Thus, genetically altered,
ESC-derived HSC might allow the proper genetic repair of
defective cells of the hematopoietic system, including those
of the innate and the adaptive immune system. However,
for transplantations of human cells histoincompatibilities
between the ESC-derived HSC and the transplanted host
might be the cause of transplant rejections.
Since it has now become possible to generate ESC-like
induced pluripotent stem cells (iPSC) from diﬀerentiated
peripheral cells [1, 2] ,H S Ca sw e l la sm a t u r eh e m a t o p o i e t i c
cellsmightinthefuturebegeneratedfromdiﬀerentiatedcells
of a patient via iPSC. Somatic cells that are either mature,
fully diﬀerentiated cells or are restricted in their ability to
develop into a limited collection of cell types can be induced
to become pluripotent, so that they exhibit higher diﬀerenti-
ationcapacity.Thisprocessiscalledreprogramming.Itisnot
yet clear whether reprogramming will always equal dediﬀer-
entiation. The original, and most widely employed method
to induce iPSC from somatic cells uses ectopic expression of
the transcription factors Oct-4, Sox-2, and Klf-4, either with
or without c-myc [1, 3–8]. However, concerns limiting clini-
cal applications of patient-derived, that is, directly converted
iPSC, include potential epigenetic diﬀerences between iPSC
and ESC [9–18], and possible modiﬁcations of the genome
by insertions and continued expression of the transcription
factors that could aﬀect the capacities of reprogrammed
iPSC to properly diﬀerentiate. In our case of interest, we
discuss some limitations to develop them into HSC and their
diﬀerentiated hematopoietic cell lineages.
Several studies have improved the procedure of the gen-
eration of iPSC from a variety of diﬀerent types of diﬀer-
entiatedcellstoﬁndthemosteﬃcientmethod.Ingeneral,at-
tempts to optimize both cell-intrinsic and exogenous factors
to achieve optimal growth, survival, and diﬀerentiation re-
quirements, ﬁrst for the transfection phase and, thereafter,
for the conversion from the diﬀerentiated cells to the iPSC
have been made [1, 3–8]. Many studies exist showing that
iPSCsharethecharacteristicofESC,thatis,theycangiverise
to all cell types of a proper body, proven by the development2 Journal of Biomedicine and Biotechnology
of chimeric animals and teratoma formation [1]. Howev-
er, these qualitative analyses do not provide information
aboutthequantitativeeﬃciencyofdevelopment.Thus,toin-
vestigate whether iPSC can replace ESC to study devel-
opment and for clinical applications, eﬃciencies of develop-
ment are needed.
Here, we summarize our experience with Oct-4/Sox-
2/Klf-4-transduced mouse embryonic ﬁbroblasts (MEF),
mousebonemarrow-derived(MBM)hematopoieticprogen-
itors, and mouse fetal liver-derived preB lymphocytes in the
in vitro generation of iPSC that show varying levels of con-
tinued expression of the transduced transcription factors in
iPSC and in diﬀerentiating hematopoietic cells. These levels
of transgenic expression relate to the potency of the iPSC to
diﬀerentiate subsequently in vitro to hematopoietic cells.
Hematopoietic development from ESC and iPSC is
one of the best-studied diﬀerentiation programs. Culture
systems have been developed that allow the diﬀerentiation of
hematopoietic lineages in vitro from ESC and iPSC [19–27]
which we have attempted to optimize for myeloid, T, NK,
and B cells [28]. However, the eﬃcient development and
maintenance of in vivo reconstituting HSC from ESC and
iPSC remains challenging. For a clinically relevant procedure
of generating transplantable HSC, ﬁrst, the best type of
diﬀerentiated cell for conversion to iPSC with the best cell-
intrinsic and extrinsic factors have to be found. Thereafter,
improved methods need to be developed to generate and
stabilize the pluripotent, long-term reconstituting potentials
of transplantable HSC.
2.ReprogrammedSomaticCellsasNewSources
for the Generation of Hematopoietic Cells
2.1. Step 1: From Diﬀerentiated Cells to iPSC. Somatic cells
were ﬁrst reprogrammed by somatic cell nuclear transfer
[29–31]. Later, lineage-associated transcription factors were
identiﬁed within a pool of 24 pluripotency-associated fac-
tors that had the potential to reprogram adult cells into
pluripotent cells upon retroviral transduction [1]. Thus,
transduction of mouse ﬁbroblasts with Oct-4, Sox-2, Klf-4,
and c-myc-generated iPSC by selection for Fbxo15 activation
that expressed pluripotency markers, generated teratomas
upon subcutaneous injection, and contributed to diﬀerent
tissues upon blastocyst injection [1]. Transcription factor-
basedreprogramming hasbeenoptimized, sothatc-mycwas
omitted and cells were selected with reactivation of Nanog
andOct-4aswellasbycheckingtheESC-likemorphology[4,
6, 8, 32]. Facts, hypotheses, and unresolved issues of cellular
reprogramming [33] and the maintenance and change of
epigeneticmemoryiniPSC[34]haverecentlybeendiscussed
extensively. As summarized by Hanna et al. [33], gene
expressions and biological characteristics of iPSC may be
inﬂuenced by genetic backgrounds (diﬀerent strains of mice,
healthy donor-derived versus patient-derived iPSC), incom-
plete or heterogeneous iPSC formation, additional or alter-
nate reprogramming factors, and transgene-expressing iPSC.
In our experiments, we have used the method of
retroviral transduction with three vectors that constitutively
express Sox-2, Oct-4, and Klf-4, respectively, and in which
the transcription factor genes are not excisable, for example,
by cre/lox-mediated deletion. We have generated iPSC lines
from MEFs, and MBM. All of our iPSC lines express ESC-
characteristic markers and form teratomas in vivo [28].
Continued transgene expression in our iPSC lines
at diﬀerent levels, even throughout diﬀerentiation to
hematopoiesis in vitro, appeared possible. When this was
measured, a remarkable diﬀerence became apparent. All
MEF-iPSC lines showed expression patterns of the three
transgenic transcription factors that were hardly above
those of the corresponding endogenous genes, while all
MBM-iPSC lines showed a markedly higher expression of
Oct-4,Klf-4 and Sox-2. It appears that a higher threshold
expressionofthethreefactorsisneededtoreprogramMBM-
iPSC than MEF-iPSC.
Distinct diﬀerentiated cells need diﬀerent culture condi-
tions, for example, diﬀerent stromal cells or other cytokines
(Figure 1). While MBM-derived cells do not grow well in
the iPSC condition without IL-6 and SCF, MEF do. This
may contribute to our observations that the eﬃciencies of
establishingMEF-derivediPSCarehigherthanthatofMBM-
derived iPSC in our experiments. This indicates that the
establishment of iPSC is more diﬃcult if the original somatic
cells from which the iPSC are intended to be induced do not
ﬁt iPSC media conditions on MEF and LIF.
The tissue culture conditions for the transduction and
subsequent in vitro conversion to iPSC appear markedly
diﬀerent. Thus, when we consider the changes that MEF
proliferating in medium alone, compared with MBM pro-
liferating in medium substituted with SCF and IL-6 have to
undergoafterviraltransductiontobecomeiPSCMEFshould
ﬁ n di te a s i e rt oc o n t i n u ep r o l i f e r a t i o na n ds u r v i v a li nL I F -
substituted media. Maybe the higher expression of the three
transduced transcription factors is favourable for the more
diﬃcult conversion of MBM to iPSC. Thus, we suggest that
the ability of cells to grow in “iPSC selection media” might
inﬂuence their eﬃciency to reprogram.
2.2. Step 2: From ESC and iPSC to HSCs and Mature
Hematopoietic Lineage Cells. For the diﬀerentiation of ESC
towards several types of mature hematopoietic cells, two
protocols have been developed—the formation of embryoid
bodies (EB) that form in suspension culture and the co-
cultivation of ESC with stromal cells. In the ﬁrst protocol,
ESC are allowed to grow in suspension in the absence of
feeder cells and LIF, diﬀerentiate spontaneously, and form
spheroidalaggregatesmimickingembryonictissues,socalled
embryoid bodies [35–38]. Cells within developing EB can
diﬀerentiate to mature cells, including hematopoietic lineage
cells [39, 40]. Hematopoietic progenitor cells, which have the
tendency to exist as mobile, nonaggregated single cells, must
befreedbydissociatingproceduresfromtheseEBaggregates.
In the second protocol, cocultivation of ESC with pre-
adipocytic stromal cells allows a two-dimensional diﬀerenti-
ationintohematopoieticcellswithouttheformationofthose
complex aggregated structures and, thus, an easier, gentle
isolation of progenitors of hematopoietic development [21,
27]. Furthermore, the use of the M-CSF-deﬁcient stromal
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Figure 1: Overview of the current understanding of the eﬃciency to induce iPSC from diﬀerent types of somatic cells, and subsequent
development of iPSC into hematopoietic cells. Dashed lines implicate lower numbers of cells developing from the former cell type compared
to full lines.
lineage cells and allows the development of T, NK, and B
lymphoid cells [21]. In our in vitro diﬀerentiation experi-
ments comparing ESC and iPSC [28]—the latter generated
by retroviral transduction with Sox-2, Oct-4, and Klf-4—we
did observe a reduced ability of iPSC-derived mesodermal-
like cells to diﬀerentiate into hematopoietic progenitors in
vitro.WhenOct-4,Sox2,andKlf-4werestillhighlyexpressed
in the diﬀerentiating cells. The overexpression of Sox-2
appeared to be inversely related to hematogenic potency
(data are summarized in Table 1).
In conclusion, our experiments suggest—as those of
others [41]—that expression of virally transduced genes
must be terminated before the induction of diﬀerentiation.
The three diﬀerent transcription factors appear to impede
hematopoietic development to diﬀerent extents. While Oct-
4 and Klf-4 appear to be tolerated at continuously elevated
levels to generate at least progenitors and precursors of T,
NK, B, and myeloid cell development, levels of Sox-2 need
to be downregulable for hematopoietic development. From
these results, it appears that overexpression of the transgenic
transcription factors inhibits development of Flk-1+ meso-
dermal to CD45+ hematopoietic progenitors. Constitutive
expression has been shown by others not to aﬀect the devel-
opmentofiPScellsintocellsofthehematopoieticsystem[42,
43]. We would expect from our results that the transgenic
expression of the three transcription factors in their iPSC
lines should be as low as that of our MEF-iPSC lines.
If normal mouse or human somatic cells are used for the
generation of iPSC the viral vectors should be deletable [44]
without mutagenic consequences or should be introduced as
proteins [45] or as synthetic modiﬁed mRNA [46].
3. Generation of HSC from ESC and
iPSCStillNeedsto BeImproved
Even if the procedures for the generation of iPSC will
eventually be faithful and eﬃcient enough to yield cells
with the same diﬀerentiation potencies as those of ESC the
subsequent eﬃcient generation of transplantable, reconsti-
tuting HSC derived from ESC and iPSC cells still has been
diﬃcult until today. Murine iPSC can be used to generate
new mouse strains in which bone marrow should, in most
cases, become the source of normal numbers of long-term
reconstituting HSC. In contrast, human iPSC, obviously, can
not be used for such an in vivo development of HSC. Hence,
the development of human HSC from ESC and iPSC must
be attempted by diﬀerentiation in tissue cultures. The most
successful method to obtain HSC in vitro from ESC is to
transduce the cells with HOXB4 [23, 25, 47–54].
However, such retroviral modiﬁcations generate cells in
which the “per cell” hematopoietic potency is still inferior
to the same number of unseparated total bone marrow cells.
Furthermore, retrovirally transduced cells carry the risk of
mutations which might lead to malignant transformations,
for example, leukaemia in the case of HOXB4 [55]. A
few studies have reported transplantations of non-HOXB4-
transduced cells resulting in long-term engraftment of both4 Journal of Biomedicine and Biotechnology
Table 1: Diﬀerentiation of MBM- and MEF-derived iPSC lines in comparison to ESC lines. Numbers of cells indicate those developed from
4 × 103 undiﬀerentiated cells (day 0). Expression levels represent amounts of mRNA determined by quantitative RT-PCR, normalized to









































×105 ×105 ×10−2 ×10−2 ×10−2 ×10−2 ×10−2 ×10−2
J1 ES 2.7 5.5 1.3 0.2 31 0.2 480 1.7
Bruce 4 ES 3.2 23 0.5 0.04 41 0.08 32 0.04
MBM-iPS A 3.1 10 1.0 6.3 2600 120 3600 83
MBM-iPS C 2.2 0.1 18 1050 11000 2500 3700 700
MEF-iPS 1 2.6 7.3 16 21 12 56 3.2 5.8
M E F - i P S 54 . 01 84 57 1 0 . 6 5 7 02 25 . 6
the lymphoid and myeloid compartments, but none of them
could reconstitute hematopoiesis in secondary transfers,
[56–59]. The question remains which kind of progenitor is
developed under these conditions.
It has been shown that yolk sac progenitors display
minimal HSC potential [60–62]. In contrast, para-aortic
splanchnopleura-derived cells can give rise to bone mar-
row reconstituting HSC which are capable of deﬁnitive
hematopoiesis [60, 61, 63]. It might be that ESC diﬀerenti-
ation in vitro generates only HSC capable of primitive, but
not of deﬁnitive hematopoietic potency. That would explain
the inability of ESC-derived hematopoietic progenitors to
generate HSC with the capacity to develop into lymphoid
cells upon transplantation. This possibility ignores the fact
that ESC and iPSC can be diﬀerentiated into primitive,
that is, erythrocytes expressing fetal-type haemoglobin,
and deﬁnitive cells, that is, lymphocytes, in vitro.H O X B 4
overexpression in hematopoietic cells derived from ESC and
from yolk sac enables the detection of transplantable HSC
[47] (Figure 1). Hence, HOXB4 works in two ways. One is
to increase the number of transplantable HSC. The second
is to make HSC transplantable by modifying the homing
receptors. Therefore, the injection of hematopoietic cells
from human ESC directly into the bone marrow results in
the detection of repopulatable HSC [49]. In conclusion, we
need to understand the molecular program that induces this
switch in greater detail to induce the formation of long-term
reconstituting HSC with deﬁnitive hematopoietic potential,
as HOXB4 does, but without retroviral insertion.
Finally, nonhematopoietic cells provide niches in bone
marrow for the proper hematopoietic diﬀerentiation that
are yet to be deﬁned, and that are missing in the culture
conditions of diﬀerentiating ESC. Furthermore, long-term
repopulating HSC that reside in the bone marrow are in a
deeply quiescent (G0) state and lose engraftment potential
during their S/G2/M transit [64–67]. The present tissue
cultureconditions favor proliferation of HSC candidate cells.
The development of conditions allowing cells to enter into
and survive in the G0/G1 phase would be another important
step towards establishing HSC in vitro.
4. Conclusions
Both stages of the in vitro development, ﬁrst, from somatic,
diﬀerentiated cells into iPSC and second, from iPSC into
HSC are still so ineﬃcient, even with murine cells, that
the clinical use of human HSC derived from a patient’s
somatic cells are far from reality. It will need many more
improvements at the various stages of reprogramming
and diﬀerentiations of cells (Figure 1). Diﬀerent somatic
cell types represent diﬀerent diﬀerentiation states, which
have diﬀerent growth abilities in vitro,d i ﬀerent suscepti-
bilities to be transduced by retroviral vectors and other
y e tu n i d e n t i ﬁ e df a c t o r s ,t h a tm a k ed i ﬀerently capable to
become reprogrammed with diﬀerent eﬃciencies. To allow
eﬀective reprogramming to iPSC, reversibly inducible or
nonintegrative methods for reprogramming need to be used,
since constitutive overexpression of reprogramming factors
has been shown to interfere with diﬀerentiation. ES cells,
and, to a lesser degree also, iPSC can be developed into
all types of hematopoietic lineages in vitro. However, the
reproducible generation of transplantable, engraftable HSC
in vitro from pluripotent cells without overexpression of
HOXB4 is still challenging (Figure 1).
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